Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Andreas, Johne"'
Autor:
Federico Amato, Rainer Strotmann, Roberto Castello, Rolf Bruns, Vishal Ghori, Andreas Johne, Karin Berghoff, Karthik Venkatakrishnan, Nadia Terranova
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 9, Pp n/a-n/a (2024)
Abstract Tepotinib is approved for the treatment of patients with non‐small‐cell lung cancer harboring MET exon 14 skipping alterations. While edema is the most prevalent adverse event (AE) and a known class effect of MET inhibitors including tep
Externí odkaz:
https://doaj.org/article/64cb53b154354915ba8eb38e3d75717f
Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study
Autor:
Dina Oksen, Patricia Prince, Emmanuelle Boutmy, Elizabeth M. Garry, Barbara Ellers‐Lenz, Adina Estrin, Andreas Johne, Patrice Verpillat, Nicolle M. Gatto
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 8, Pp 1990-1998 (2022)
Abstract Real‐world data (RWD) reflecting patient treatment in routine clinical practice can be used to develop external control groups for single‐arm trials. External controls can provide valuable benchmark results on potential comparator drug e
Externí odkaz:
https://doaj.org/article/2ca7f2e918c842a88cefcea8b7b2b902
Autor:
Wenyuan Xiong, Manja Friese‐Hamim, Andreas Johne, Christopher Stroh, Manfred Klevesath, Gerald S. Falchook, David S. Hong, Pascal Girard, Samer El Bawab
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 5, Pp 428-440 (2021)
Abstract Tepotinib is a highly selective and potent MET inhibitor in development for the treatment of patients with solid tumors. Given the favorable tolerability and safety profiles up to the maximum tested dose in the first‐in‐human (FIH) trial
Externí odkaz:
https://doaj.org/article/336092d3d9d74e2798fde9141c4ad366
Autor:
Andreas Becker, Emily C. Martin, David Y. Mitchell, Roland Grenningloh, Andrew T. Bender, Julien Laurent, Harald Mackenzie, Andreas Johne
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 2, Pp 325-336 (2020)
Bruton's tyrosine kinase (BTK) is a key regulator of B cell receptor and Fc receptor signaling, and a rational therapeutic target for autoimmune diseases. This first‐in‐human phase I, double‐blind, placebo‐controlled trial investigated the sa
Externí odkaz:
https://doaj.org/article/d2c9cd5493264b6eba52d7fefaa2b7b2
Autor:
Yi-Long Wu, Andreas Johne, Rolf Bruns, Karin Berghoff, Jun Zhao, Yiping Zhang, James Chih-Hsin Yang, Sang Won Shin, Shun Lu, Ying Cheng, Ross Andrew Soo, Dong-Wan Kim, Jianying Zhou, Te-Chun Hsia, Azura Rozila Ahmad, Chong Kin Liam
Duration of PFS in the patient subgroup with MET amplification
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c01e965a7a4751400c9130eefc53d8
https://doi.org/10.1158/1078-0432.22820141.v1
https://doi.org/10.1158/1078-0432.22820141.v1
Autor:
Yi-Long Wu, Andreas Johne, Rolf Bruns, Karin Berghoff, Jun Zhao, Yiping Zhang, James Chih-Hsin Yang, Sang Won Shin, Shun Lu, Ying Cheng, Ross Andrew Soo, Dong-Wan Kim, Jianying Zhou, Te-Chun Hsia, Azura Rozila Ahmad, Chong Kin Liam
Representativeness of study population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80a394bfe0e9c134b3c5f2a22777c1b6
https://doi.org/10.1158/1078-0432.22820126
https://doi.org/10.1158/1078-0432.22820126
Autor:
Yi-Long Wu, Andreas Johne, Rolf Bruns, Karin Berghoff, Jun Zhao, Yiping Zhang, James Chih-Hsin Yang, Sang Won Shin, Shun Lu, Ying Cheng, Ross Andrew Soo, Dong-Wan Kim, Jianying Zhou, Te-Chun Hsia, Azura Rozila Ahmad, Chong Kin Liam
Plain language summary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::502e98744f28781160442e0abf336405
https://doi.org/10.1158/1078-0432.22665304
https://doi.org/10.1158/1078-0432.22665304
Autor:
Yi-Long Wu, Andreas Johne, Rolf Bruns, Karin Berghoff, Jun Zhao, Yiping Zhang, James Chih-Hsin Yang, Sang Won Shin, Shun Lu, Ying Cheng, Ross Andrew Soo, Dong-Wan Kim, Jianying Zhou, Te-Chun Hsia, Azura Rozila Ahmad, Chong Kin Liam
Purpose:The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3, 2021).Patients and Methods:Adults
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f701c66d9574733bd03494fc801a300
https://doi.org/10.1158/1078-0432.c.6608869.v1
https://doi.org/10.1158/1078-0432.c.6608869.v1
Autor:
David S. Hong, Samer El Bawab, Pascal Girard, Manja Friese-Hamim, Friedhelm Bladt, Andreas Johne, Uz Stammberger, Rolf Bruns, Manfred Klevesath, Daniel V. Catenacci, Ghazaleh Eskandari, Filip Janku, Sarina A. Piha-Paul, Siqing Fu, Wenyuan Xiong, Hesham M. Amin, Razelle Kurzrock, Gerald S. Falchook
Purpose:Tepotinib is an oral, potent, highly selective MET inhibitor. This first-in-man phase I trial investigated the MTD of tepotinib to determine the recommended phase II dose (RP2D).Patients and Methods:Patients received tepotinib orally accordin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::671f44bbd9f87afda836e289bffa0f98
https://doi.org/10.1158/1078-0432.c.6529907
https://doi.org/10.1158/1078-0432.c.6529907
Autor:
David S. Hong, Samer El Bawab, Pascal Girard, Manja Friese-Hamim, Friedhelm Bladt, Andreas Johne, Uz Stammberger, Rolf Bruns, Manfred Klevesath, Daniel V. Catenacci, Ghazaleh Eskandari, Filip Janku, Sarina A. Piha-Paul, Siqing Fu, Wenyuan Xiong, Hesham M. Amin, Razelle Kurzrock, Gerald S. Falchook
Supplementary information showing details of study criteria, bioasssays, preclinical modelling, PK data, safety and efficacy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7690cb145a7b5a77f8a21817acc152e7
https://doi.org/10.1158/1078-0432.22478273
https://doi.org/10.1158/1078-0432.22478273